26 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))
14 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market
14 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease
14 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson’s Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada
14 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson’s Disease and Neuropathic Pain
